Back to Stocks

SNES

SenesTech, Inc.
2 filings tracked
technologybiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

SenesTech is demonstrating a successful pivot toward a scalable commercial model, anchored by the rapid ascent of its Evolve product line.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of commercial inflection, the hard numbers reveal a company struggling to find genuine growth. Revenue remained essentially flat, increasing by a negligible 2% year-over-year, while operating losses deepened by 27% to $2.12 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SNES filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic venture-stage trade-off: a high-margin, innovative product line facing a challenging path to profitability. On one hand, the expansion of gross margins and the successful launch of Evolve Mouse and Evolve Rat suggest a viable product-market fit. On the other hand, the flat top-line growth and accelerating operating losses indicate that the company has yet to achieve the critical mass necessary to sustain itself without external funding. Investors are now weighing the impact of a leadership change and the resolution of key legal disputes against a backdrop of persistent cash burn. The transition to a new CEO may provide the operational rigor needed to optimize the sales force, but the looming threat of warrant exercises and potential equity offerings remains a primary concern. The ultimate trajectory of the stock will likely depend on whether the company can convert its high gross margins into actual net income before its cash reserves deplete.

Selected Quarter

Core Takeaway

The company has a proven, high-margin product in Evolve, but is failing to scale revenue fast enough to offset its operational burn.

Investor Lens

The trade-off between the potential of a disruptive pest-control technology and the immediate risk of equity dilution.

Watch Next

Q2 2026 revenue growth rate and any further ATM equity offerings.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.17Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 13

Gross margins increased to 68.6% due to production efficiency and product mix.

margin expansion
70%
bearishMay 13

Net loss widened to $2.06 million as SG&A expenses surged 31%.

earnings miss
60%
neutralMay 13

Appointment of Michael Edell as President and CEO effective May 6, 2026.

management change
50%
bearishMay 13

Over 2.8 million warrants outstanding with low exercise prices create significant overhang.

dilution risk
80%
bullishMay 13

Gross margins increased to 68.6% due to production efficiency and product mix.

margin expansion
70%
bearishMay 13

Net loss widened to $2.06 million as SG&A expenses surged 31%.

earnings miss
60%
neutralMay 13

Appointment of Michael Edell as President and CEO effective May 6, 2026.

management change
50%
bearishMay 13

Over 2.8 million warrants outstanding with low exercise prices create significant overhang.

dilution risk
80%

Filing History

10-QMay 13, 2026
Expand Sequence

The Q1 2026 filing presents a classic venture-stage trade-off: a high-margin, innovative product line facing a challenging path to profitability. On one hand, the expansion of gross margins and the successful launch of Evolve Mouse and Evolve Rat suggest a viable product-market fit. On the other hand, the flat top-line growth and accelerating operating losses indicate that the company has yet to achieve the critical mass necessary to sustain itself without external funding. Investors are now weighing the impact of a leadership change and the resolution of key legal disputes against a backdrop of persistent cash burn. The transition to a new CEO may provide the operational rigor needed to optimize the sales force, but the looming threat of warrant exercises and potential equity offerings remains a primary concern. The ultimate trajectory of the stock will likely depend on whether the company can convert its high gross margins into actual net income before its cash reserves deplete.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.